Difference between revisions of "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"

From OmniJournal
Jump to navigation Jump to search
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://www.nature.com/articles/s41421-020-01...")
 
 
Line 23: Line 23:
 
== Major Issues ==
 
== Major Issues ==
  
No major issues identified.
+
No major issues identified at this time.
  
 
== Minor Issues ==
 
== Minor Issues ==
  
No minor issues identified.
+
No minor issues identified at this time.
  
 
== Impact ==
 
== Impact ==

Latest revision as of 17:09, 22 July 2020

Publication
Title
Authors
  • Jia Liu
  • Ruiyuan Cao
  • Mingyue Xu
  • ...
  • Manli Wang
Journal Cell Discovery
Date March 18, 2020

In vitro study demonstrating that hydroxychloroquine is effective in inhibiting SARS-CoV-2 infection by blocking the transport of SARS-CoV-2 from EEs to Els, which is a requirement to release the viral genome. Authors conclude that hydroxychloroquine’s in vitro effect of inhibiting viral replication in combination with its anti-inflammatory function makes the drug a good candidate for treatment of COVID-19.

Major Issues

No major issues identified at this time.

Minor Issues

No minor issues identified at this time.

Impact

This study demonstrated in vitro efficacy of hydroxychloroquine in blocking a necessary step in viral replication of SARS-CoV-2.

Article Revisions

None at this time.

References